Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

744.50 +1.15 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 Next >
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Regeneron Reports Third Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
Micron, Biogen, and Regeneron are three stocks that appear oversold and could present substantial buying opportunities for investors seeking recovery plays. 
Via MarketBeat
Topics ETFs Earnings
Exposures Financial
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Provides Update on Biologics License Application for Linvoseltamab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Reports Second Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
CPI Data Sparks Rally in Biotech Stocks
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.